Novel preparative regimens in hematopoietic stem cell transplantation

dc.contributor.authorLekakis, Lazaros
dc.contributor.authorSilva, Leandro de Padua [UNIFESP]
dc.contributor.authorLima, Marcos de
dc.contributor.institutionUniv Texas MD Anderson Canc Ctr
dc.contributor.institutionUniv Kentucky
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:51:33Z
dc.date.available2016-01-24T13:51:33Z
dc.date.issued2008-07-01
dc.description.abstractHematopoietic stem cell transplantation is an established treatment modality for malignant and non-malignant diseases. Prior to the infusion of allogeneic or autologous cells, patients usually receive radiation or chemotherapy. This preparative' or 'conditioning' regimen provides treatment for the underlying disease and is expected to impair the recipient's immune system and allow engraftment.The last decade witnessed a significant reduction in treatment-related mortality, in great part a result of less toxic preparative regimens and improvements in supportive care. Another important trend has been the incorporation of newer drugs to 'classic' conditioning regimens, as illustrated by the addition of rituximab to BEAM and other combinations. It is expected that this trend will continue leading to increased cure rates by incorporation of targeted therapies to hematopoietic transplant. the next decade will likely witness further integration of new preparative regimens with graft engineering, and pharmacologic, cellular and immunologic post transplant interventions. the design of creative clinical trials that will allow the critical evaluation of the role of these new approaches in transplantation will also be a major challenge to the transplant community in the years to come.In this article, we review newer transplant conditioning regimens and discuss their indications and future directions in this rapidly changing landscape.en
dc.description.affiliationUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat Cellular Therapy, Houston, TX 77030 USA
dc.description.affiliationUniv Kentucky, Dept Hematol Med Oncol & Blood & Marrow Transplan, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA
dc.description.affiliationUniversidade Federal de São Paulo, Dept Hematol & Oncol & Blood & Marrow Transplanta, EPM, BR-04023900 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Hematol & Oncol & Blood & Marrow Transplanta, EPM, BR-04023900 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1923-1935
dc.identifierhttp://dx.doi.org/10.2174/138161208785061409
dc.identifier.citationCurrent Pharmaceutical Design. Sharjah: Bentham Science Publ Ltd, v. 14, n. 20, p. 1923-1935, 2008.
dc.identifier.doi10.2174/138161208785061409
dc.identifier.issn1381-6128
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/30798
dc.identifier.wosWOS:000259447800002
dc.language.isoeng
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCurrent Pharmaceutical Design
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjecthematopoietic stem cell transplantationen
dc.subjectpreparative regimensen
dc.subjectconditioningen
dc.subjecthematologic malignanciesen
dc.titleNovel preparative regimens in hematopoietic stem cell transplantationen
dc.typeinfo:eu-repo/semantics/article
Arquivos